

Donate

Menu

Shows

Support Us

Sign in



The ACA subsidies at the heart of the shutdown fight

00:00 07:00



JAN 23, 2015

New effort ranks drugmakers by impact

The idea is to give companies another incentive to treat infectious diseases.

by Dan Gorenstein



Save



Share

Pharmaceutical companies have one very obvious reason to avoid developing drugs and vaccines for infectious diseases like malaria and tuberculosis: There's basically no money in it.

That's because most people with those conditions are poor and have little means to pay. So what kind of incentive do you need to get drugmakers to take on global health epidemics? The answer may be a new [index](#) that ranks companies by who has the most effective drugs.

Click the media player above to hear more.

RELATED TOPICS

Tagged as:

geneva

global health

malaria



Our best stories, straight to your inbox

Sign up for the Marketplace newsletter to get stories that help you live smarter — plus analysis, explainers and our song of the week — sent to you every Friday morning.

SUBSCRIBE

[See Terms](#)

Latest Stories

New private data shows slow hiring

In today's housing market, cash still rules

What an auction yard can tell us about the construction industry

Latest Episodes

[View All Shows](#)





11 hours ago

4:57



a day ago

25:45



4 days ago

26:11



2 months ago

35:26



Daily business news and economic stories

DONATE

About Us

Staff

Careers

Support Marketplace

Contact Us

Newsletters

Get texts

Stay Connected to Marketplace:

Marketplace Shop

© 2025 Minnesota Public Radio. All Rights Reserved. Marketplace is a division of MPR's 501 (c)(3).
EIN: 41-0953924

[Privacy Policy](#) | [Terms of Use](#)